Recombinant human endostatin combined with platinum compounds for malignant pleural effusion: an overview of systematic reviews_West China Medical Journal

Authors：

LI Zeyun ¹ , LAN Qingxia ¹ , LIU Chengxin ¹ ,  CAO Yang ²

1. The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, P. R. China;
2. Department of Oncology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, P. R. China;

Corresponding author：

CAO Yang, Email: 393556828@qq.com

Keywords：

Recombinant human endostatin; platinum compounds; malignant pleural effusion; systematic review; overview

DOI：

10.7507/1002-0179.202008254

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To overview the systematic reviews of recombinant human endostatin combined with platinum compounds for malignant pleural effusion (MPE). Methods According to the inclusion and exclusion criteria and searching strategies, we screened the systematic reviews of recombinant human endostatin combined with platinum compounds for the treatment of MPE by searching the Embase, PubMed, Clinical Trials, Cochrane Library, China National Knowledge Infrastructure, CQVIP Database and Wanfang Database. The searching time was from January 1999 to December 2021. The methodological quality was evaluated using AMSTAR 2 tool, the report quality was evaluated using PRISMA statement, and the evidence quality of the outcome indicators was graded according to the GRADE system. Finally, RevMan 5.3 software was used to quantitatively merge and analyze the original research effect values of the main outcome indicators with low level of evidence. Results A total of 9 systematic reviews/meta-analyses involving 8 outcome indicators and totally 50 outcomes were included. The average PRISMA scale score was 22.28±1.37, with 6 reports being relatively complete and 3 reports having certain reporting defects. The overall methodological quality of the 9 systematic reviews was extremely low. Most of the 50 outcomes were graded as “low” (31 outcomes) or “intermediate” (18 outcomes) quality. The results of 9 systematic reviews all showed that the clinical efficacy of dual therapy was more satisfactory than that of platinum-based preparations in the treatment of MPE, and re-quantitative analysis also confirmed that there was no statistically significant difference in the incidence of adverse events between the two treatments (P>0.05). Conclusions Considering the existing evidence and the results of meta-analysis, the dual therapy composed of recombinant human endostatin and platinum compounds is more effective in the treatment of MPE, and there is no difference in the incidence of related adverse events. However, because of its poor methodological quality and the low level of evidence, the above conclusions can only provide a certain reference and need to be confirmed by further research.

Citation： LI Zeyun, LAN Qingxia, LIU Chengxin, CAO Yang. Recombinant human endostatin combined with platinum compounds for malignant pleural effusion: an overview of systematic reviews. West China Medical Journal, 2022, 37(1): 48-55. doi: 10.7507/1002-0179.202008254 Copy

1.	Clive A, Jones H, Bhatnagar R, et al. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev, 2016(5): CD010529.
2.	Heffner JE. Management of the patient with a malignant pleural effusion. Semin Respir Crit Care Med, 2010, 31(6): 723-733.
3.	Roberts ME, Neville E, Berrisford RG, et al. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax, 2010, 65(Suppl 2): ii32-ii40.
4.	Penz E, Watt KN, Hergott CA, et al. Management of malignant pleural effusion: challenges and solutions. Cancer Manag Res, 2017, 9: 229-241.
5.	Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. J Clin Epidemiol, 2009, 62(10): 1006-1012.
6.	Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017, 358: j4008.
7.	Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol, 2011, 64(4): 380-382.
8.	Liang R, Xie HY, Lin Y, et al. Intraperitoneal perfusion therapy of endostar combined with platinum chemotherapy for malignant serous effusions: a meta-analysis. Asian Pac J Cancer Prev, 2015, 16(18): 8637-8644.
9.	韩娜娜, 徐细明. 恩度联合化疗药物灌注治疗恶性胸腹腔积液效果的系统评价. 中国医药导报, 2015, 12(28): 103-107.
10.	谢海英. 恩度联合铂类药物腔内灌注治疗恶性浆膜腔积液随机对照试验的 meta 分析. 南宁: 广西医科大学, 2015.
11.	Biaoxue R, Xiguang C, Hua L, et al. Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis. BMC Cancer, 2016, 16(1): 888.
12.	杨闽洁, 何炜, 王峰, 等. 重组人血管内皮抑制素联合顺铂胸腔灌注化疗治疗恶性胸腔积液的 Meta 分析. 临床肿瘤学杂志, 2015, 20(12): 1117-1123.
13.	蒋俊, 解佳奇, 张丽, 等. 重组人血管内皮抑素联合顺铂治疗恶性胸腔积液的 Meta 分析. 实用癌症杂志, 2016, 31(3): 411-416.
14.	刘自力, 黄礼年, 王斌, 等. 恩度联合顺铂治疗非小细胞肺癌合并恶性胸腔积液的 Meta 分析. 中国循证医学杂志, 2016, 16(5): 557-563.
15.	孙园园, 余正. 恩度联合顺铂治疗恶性胸腔积液的 Meta 分析. 现代商贸工业, 2016, 37(33): 166-169.
16.	杨惠萍, 陈婷, 应苗法. 重组人血管内皮抑制素联合顺铂腔内注射治疗恶性胸腔积液疗效和安全性的 Meta 分析. 肿瘤学杂志, 2016, 22(5): 410-416.
17.	刘明涛, 闫鹏鹏, 常刚, 等. 胸腔内注入恩度联合铂类制剂治疗恶性胸腔积液疗效及安全性的系统评价. 中国医师杂志, 2017, 19(2): 257-262.
18.	吕传峰, 王珊, 袁方, 等. 重组人血管内皮抑素联合顺铂胸腔灌注治疗恶性胸腔积液近期疗效的 Meta 分析. 医药导报, 2017, 36(5): 558-563.
19.	赵子舒, 杨雁鸿, 王小玉, 等. 重组人血管内皮抑制素联合顺铂治疗非小细胞肺癌恶性胸腔积液的疗效及安全性的 Meta 分析. 亚洲肿瘤科病例研究, 2018, 7(3): 17-25.
20.	周燕群, 郭勇, 杨笑奇. 恩度联合顺铂腔内注射治疗肺癌合并恶性胸腔积液 meta 分析. 实用肿瘤杂志, 2018, 33(6): 553-560.
21.	Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax, 2009, 64(2): 139-143.
22.	Chen Y, Mathy NW, Lu H. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (Review). Mol Med Rep, 2018, 17(6): 8019-8030.
23.	Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res, 2006, 312(5): 594-607.
24.	Zhao WY, Chen DY, Chen JH, et al. Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites. Cell Biochem Biophys, 2014, 70(1): 623-628.

1. Clive A, Jones H, Bhatnagar R, et al. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev, 2016(5): CD010529.
2. Heffner JE. Management of the patient with a malignant pleural effusion. Semin Respir Crit Care Med, 2010, 31(6): 723-733.
3. Roberts ME, Neville E, Berrisford RG, et al. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax, 2010, 65(Suppl 2): ii32-ii40.
4. Penz E, Watt KN, Hergott CA, et al. Management of malignant pleural effusion: challenges and solutions. Cancer Manag Res, 2017, 9: 229-241.
5. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. J Clin Epidemiol, 2009, 62(10): 1006-1012.
6. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017, 358: j4008.
7. Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol, 2011, 64(4): 380-382.
8. Liang R, Xie HY, Lin Y, et al. Intraperitoneal perfusion therapy of endostar combined with platinum chemotherapy for malignant serous effusions: a meta-analysis. Asian Pac J Cancer Prev, 2015, 16(18): 8637-8644.
9. 韩娜娜, 徐细明. 恩度联合化疗药物灌注治疗恶性胸腹腔积液效果的系统评价. 中国医药导报, 2015, 12(28): 103-107.
10. 谢海英. 恩度联合铂类药物腔内灌注治疗恶性浆膜腔积液随机对照试验的 meta 分析. 南宁: 广西医科大学, 2015.
11. Biaoxue R, Xiguang C, Hua L, et al. Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis. BMC Cancer, 2016, 16(1): 888.
12. 杨闽洁, 何炜, 王峰, 等. 重组人血管内皮抑制素联合顺铂胸腔灌注化疗治疗恶性胸腔积液的 Meta 分析. 临床肿瘤学杂志, 2015, 20(12): 1117-1123.
13. 蒋俊, 解佳奇, 张丽, 等. 重组人血管内皮抑素联合顺铂治疗恶性胸腔积液的 Meta 分析. 实用癌症杂志, 2016, 31(3): 411-416.
14. 刘自力, 黄礼年, 王斌, 等. 恩度联合顺铂治疗非小细胞肺癌合并恶性胸腔积液的 Meta 分析. 中国循证医学杂志, 2016, 16(5): 557-563.
15. 孙园园, 余正. 恩度联合顺铂治疗恶性胸腔积液的 Meta 分析. 现代商贸工业, 2016, 37(33): 166-169.
16. 杨惠萍, 陈婷, 应苗法. 重组人血管内皮抑制素联合顺铂腔内注射治疗恶性胸腔积液疗效和安全性的 Meta 分析. 肿瘤学杂志, 2016, 22(5): 410-416.
17. 刘明涛, 闫鹏鹏, 常刚, 等. 胸腔内注入恩度联合铂类制剂治疗恶性胸腔积液疗效及安全性的系统评价. 中国医师杂志, 2017, 19(2): 257-262.
18. 吕传峰, 王珊, 袁方, 等. 重组人血管内皮抑素联合顺铂胸腔灌注治疗恶性胸腔积液近期疗效的 Meta 分析. 医药导报, 2017, 36(5): 558-563.
19. 赵子舒, 杨雁鸿, 王小玉, 等. 重组人血管内皮抑制素联合顺铂治疗非小细胞肺癌恶性胸腔积液的疗效及安全性的 Meta 分析. 亚洲肿瘤科病例研究, 2018, 7(3): 17-25.
20. 周燕群, 郭勇, 杨笑奇. 恩度联合顺铂腔内注射治疗肺癌合并恶性胸腔积液 meta 分析. 实用肿瘤杂志, 2018, 33(6): 553-560.
21. Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax, 2009, 64(2): 139-143.
22. Chen Y, Mathy NW, Lu H. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (Review). Mol Med Rep, 2018, 17(6): 8019-8030.
23. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res, 2006, 312(5): 594-607.
24. Zhao WY, Chen DY, Chen JH, et al. Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites. Cell Biochem Biophys, 2014, 70(1): 623-628.

West China Medical Journal

Recombinant human endostatin combined with platinum compounds for malignant pleural effusion: an overview of systematic reviews

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content